BR112022015628A2 - Vacina de sars-cov-2 - Google Patents
Vacina de sars-cov-2Info
- Publication number
- BR112022015628A2 BR112022015628A2 BR112022015628A BR112022015628A BR112022015628A2 BR 112022015628 A2 BR112022015628 A2 BR 112022015628A2 BR 112022015628 A BR112022015628 A BR 112022015628A BR 112022015628 A BR112022015628 A BR 112022015628A BR 112022015628 A2 BR112022015628 A2 BR 112022015628A2
- Authority
- BR
- Brazil
- Prior art keywords
- cov
- sars
- vaccine
- individual
- nucleic acid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062972886P | 2020-02-11 | 2020-02-11 | |
| PCT/US2021/017709 WO2021163365A1 (en) | 2020-02-11 | 2021-02-11 | Sars-cov-2 vaccine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022015628A2 true BR112022015628A2 (pt) | 2022-09-27 |
Family
ID=74860458
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022015628A BR112022015628A2 (pt) | 2020-02-11 | 2021-02-11 | Vacina de sars-cov-2 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230113170A1 (enExample) |
| EP (1) | EP4103229A1 (enExample) |
| JP (2) | JP2023513693A (enExample) |
| KR (1) | KR20220140586A (enExample) |
| CN (1) | CN115515627A (enExample) |
| AU (1) | AU2021221127A1 (enExample) |
| BR (1) | BR112022015628A2 (enExample) |
| CA (1) | CA3170322A1 (enExample) |
| IL (2) | IL295301A (enExample) |
| MX (1) | MX2022009836A (enExample) |
| WO (1) | WO2021163365A1 (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20210260181A1 (en) * | 2014-09-16 | 2021-08-26 | Altimmune, Inc | Coronavirus immunogenic compositions and uses thereof |
| DE20164728T1 (de) | 2015-10-22 | 2021-09-30 | Modernatx, Inc. | Impfstoffe gegen atemwegsvirus |
| US12194089B2 (en) | 2020-02-04 | 2025-01-14 | CureVac SE | Coronavirus vaccine |
| US11241493B2 (en) | 2020-02-04 | 2022-02-08 | Curevac Ag | Coronavirus vaccine |
| CA3167052A1 (en) | 2020-02-14 | 2021-08-19 | Mary Jo Hauser | Vaccines and uses thereof to induce an immune response to sars-cov2 |
| WO2021170869A1 (en) * | 2020-02-27 | 2021-09-02 | Katholieke Universiteit Leuven | Coronavirus vaccines |
| CN118490818A (zh) | 2020-04-22 | 2024-08-16 | 生物技术欧洲股份公司 | 冠状病毒疫苗 |
| US20230174592A1 (en) * | 2020-04-30 | 2023-06-08 | Yang Sheng Tang Company, Ltd. | Detection reagent for screening blocking agent of coronavirus infections, and detection method |
| WO2021229270A1 (es) | 2020-05-13 | 2021-11-18 | Laboratorio Avi-Mex, S.A. De C.V. | Vacuna recombinante contra covid-19 en vector viral |
| AU2021279079A1 (en) | 2020-05-29 | 2022-12-15 | Board Of Regents, The University Of Texas System | Engineered coronavirus spike (s) protein and methods of use thereof |
| WO2021249011A1 (en) | 2020-06-10 | 2021-12-16 | Sichuan Clover Biopharmaceuticals, Inc. | Hiv vaccine compositions, methods, and uses thereof |
| WO2021249116A1 (en) | 2020-06-10 | 2021-12-16 | Sichuan Clover Biopharmaceuticals, Inc. | Coronavirus vaccine compositions, methods, and uses thereof |
| WO2022041760A1 (en) | 2020-08-31 | 2022-03-03 | Sichuan Clover Biopharmaceuticals, Inc. | Methods and compositions for purification of trimeric fusion proteins |
| IL302645A (en) * | 2020-11-03 | 2023-07-01 | The Wistrar Inst Of Anatomy And Biology | Dna encoded nanoparticles and method of use thereof as a coronavirus disease 2019 (covid-19) vaccine |
| EP4263576A4 (en) * | 2020-12-18 | 2025-08-13 | Scripps Research Inst | IMMUNOGENIC COMPOSITIONS |
| MX2023007574A (es) | 2020-12-22 | 2023-09-29 | CureVac SE | "vacuna de arn contra variantes de sars-cov-2. |
| CN113633764B (zh) * | 2021-09-02 | 2024-05-14 | 中国食品药品检定研究院 | 一种含佐剂的新冠dna疫苗 |
| CN113527522B (zh) * | 2021-09-13 | 2021-12-21 | 深圳市瑞吉生物科技有限公司 | 一种新冠病毒三聚体重组蛋白、DNA、mRNA及应用和mRNA疫苗 |
| CN115806624A (zh) * | 2021-09-14 | 2023-03-17 | 中国人民解放军陆军军医大学第一附属医院 | 融合新冠病毒亚单位蛋白和IgG1-Fc区域的蛋白及在疫苗开发中的用途 |
| WO2023047349A1 (en) * | 2021-09-24 | 2023-03-30 | Janssen Pharmaceuticals, Inc. | Stabilized coronavirus spike protein fusion proteins |
| WO2023047348A1 (en) * | 2021-09-24 | 2023-03-30 | Janssen Pharmaceuticals, Inc. | Stabilized corona virus spike protein fusion proteins |
| EP4238577A3 (en) | 2021-10-22 | 2023-12-06 | BioNTech SE | Compositions for administration of different doses of rna |
| WO2023089556A1 (en) | 2021-11-22 | 2023-05-25 | Pfizer Inc. | Reducing risk of antigen mimicry in immunogenic medicaments |
| WO2023094713A2 (en) | 2021-11-29 | 2023-06-01 | BioNTech SE | Coronavirus vaccine |
| US20230167157A1 (en) * | 2021-11-29 | 2023-06-01 | Arabian Gulf University | ANTIGENIC DETERMINANTS PROTECTIVE IMMUNITY, SERODIAGNOSTIC AND MULTIVALENT SUBUNITS PRECISION VACCINE AGAINST SARS-CoV-2 |
| US12186387B2 (en) | 2021-11-29 | 2025-01-07 | BioNTech SE | Coronavirus vaccine |
| US12616747B2 (en) | 2021-12-03 | 2026-05-05 | Board Of Regents, The University Of Texas System | Stabilized beta-coronavirus antigens |
| CN114989308B (zh) * | 2022-05-12 | 2023-04-04 | 中国科学院微生物研究所 | 新冠病毒嵌合核酸疫苗及其用途 |
| US11878055B1 (en) | 2022-06-26 | 2024-01-23 | BioNTech SE | Coronavirus vaccine |
| CN115287265B (zh) * | 2022-07-12 | 2023-05-23 | 四川大学华西医院 | 多能活性制剂诱发恒河猴抵抗新冠突变体的免疫防治模型 |
| EP4604995A1 (en) | 2022-10-17 | 2025-08-27 | BioNTech SE | Combination vaccines against coronavirus infection, influenza infection, and/or rsv infection |
| WO2024089638A1 (en) | 2022-10-28 | 2024-05-02 | Glaxosmithkline Biologicals Sa | Nucleic acid based vaccine |
| US20240156958A1 (en) * | 2022-11-02 | 2024-05-16 | Design-Zyme LLC | Self-adjuvanting multi-protein complexes for modular vaccine production |
| WO2025106754A1 (en) | 2023-11-15 | 2025-05-22 | BioNTech SE | Coronavirus vaccine |
| KR20260015501A (ko) * | 2024-07-25 | 2026-02-03 | 아주대학교산학협력단 | 다중 에피토프 기반 사스코로나바이러스-2 백신 조성물 |
| WO2026148356A1 (en) | 2025-01-06 | 2026-07-09 | BioNTech SE | Coronavirus and influenza immunogenic combinations |
| CN121041421B (zh) * | 2025-09-04 | 2026-07-17 | 黑龙江八一农垦大学 | 一种猪德尔塔冠状病毒S1蛋白纳米颗粒疫苗CTDnps及其应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
| US5091309A (en) | 1986-01-16 | 1992-02-25 | Washington University | Sindbis virus vectors |
| US5217879A (en) | 1989-01-12 | 1993-06-08 | Washington University | Infectious Sindbis virus vectors |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5643578A (en) | 1992-03-23 | 1997-07-01 | University Of Massachusetts Medical Center | Immunization by inoculation of DNA transcription unit |
| EP0671926B1 (en) | 1992-08-11 | 2002-11-13 | President And Fellows Of Harvard College | Immunomodulatory peptides |
| US5593972A (en) | 1993-01-26 | 1997-01-14 | The Wistar Institute | Genetic immunization |
| FR2705686B1 (fr) | 1993-05-28 | 1995-08-18 | Transgene Sa | Nouveaux adénovirus défectifs et lignées de complémentation correspondantes. |
| CA2144040A1 (fr) | 1993-07-13 | 1995-01-26 | Michel Perricaudet | Vecteurs adenoviraux defectifs et utilisation en therapie genique |
| WO1995016772A1 (en) | 1993-12-14 | 1995-06-22 | Cornell Research Foundation, Inc. | Adenovirus gene expression system |
| EP0784690B1 (en) | 1994-06-10 | 2006-08-16 | Genvec, Inc. | Complementary adenoviral vector systems and cell lines |
| US5851806A (en) | 1994-06-10 | 1998-12-22 | Genvec, Inc. | Complementary adenoviral systems and cell lines |
| IL116816A (en) | 1995-01-20 | 2003-05-29 | Rhone Poulenc Rorer Sa | Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof |
| US5837511A (en) | 1995-10-02 | 1998-11-17 | Cornell Research Foundation, Inc. | Non-group C adenoviral vectors |
| EP1425045A4 (en) | 2001-09-13 | 2004-11-10 | Genvec Inc | ADENOVIRAL VECTOR AND RELEVANT SYSTEM AND METHOD FOR THE PRODUCTION AND USE THEREOF |
| WO2018081318A1 (en) * | 2016-10-25 | 2018-05-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Prefusion coronavirus spike proteins and their use |
| AU2019285048B2 (en) * | 2018-06-13 | 2023-06-08 | The Scripps Research Institute | Nanoparticle vaccines with novel structural components |
-
2021
- 2021-02-11 CN CN202180027866.XA patent/CN115515627A/zh active Pending
- 2021-02-11 AU AU2021221127A patent/AU2021221127A1/en active Pending
- 2021-02-11 IL IL295301A patent/IL295301A/en unknown
- 2021-02-11 KR KR1020227031250A patent/KR20220140586A/ko active Pending
- 2021-02-11 CA CA3170322A patent/CA3170322A1/en active Pending
- 2021-02-11 WO PCT/US2021/017709 patent/WO2021163365A1/en not_active Ceased
- 2021-02-11 US US17/798,021 patent/US20230113170A1/en not_active Abandoned
- 2021-02-11 EP EP21710716.8A patent/EP4103229A1/en active Pending
- 2021-02-11 JP JP2022548435A patent/JP2023513693A/ja not_active Withdrawn
- 2021-02-11 MX MX2022009836A patent/MX2022009836A/es unknown
- 2021-02-11 BR BR112022015628A patent/BR112022015628A2/pt unknown
-
2025
- 2025-10-20 IL IL324082A patent/IL324082A/en unknown
- 2025-12-22 JP JP2025272749A patent/JP2026040566A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023513693A (ja) | 2023-04-03 |
| CA3170322A1 (en) | 2021-08-19 |
| JP2026040566A (ja) | 2026-03-09 |
| CN115515627A (zh) | 2022-12-23 |
| MX2022009836A (es) | 2022-11-30 |
| AU2021221127A1 (en) | 2022-09-22 |
| EP4103229A1 (en) | 2022-12-21 |
| IL324082A (en) | 2025-12-01 |
| KR20220140586A (ko) | 2022-10-18 |
| IL295301A (en) | 2022-10-01 |
| WO2021163365A1 (en) | 2021-08-19 |
| US20230113170A1 (en) | 2023-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022009836A (es) | Vacuna para sars-cov-2. | |
| PE20231439A1 (es) | Proteinas f de hmpv estabilizadas por prefusion | |
| BR112023005674A2 (pt) | Construtos anti-cd93 e usos dos mesmos | |
| BR112022026733A2 (pt) | Imunógenos estabilizados de proteína spike (s) de coronavírus e vacinas relacionadas | |
| BR112021005769A2 (pt) | proteínas de ligação a dll3 e métodos de uso | |
| CY1123403T1 (el) | Τροποποιημενα κυτταρα ξενιστες και χρησεις αυτων | |
| EP4599847A3 (en) | Prefusion coronavirus spike proteins and their use | |
| CY1125387T1 (el) | Αντιγονα, διαβιβαστες, συνθεσεις του ιου της ανθρωπινης ανοσοανεπαρκειας, και μεθοδοι χρησης τους | |
| BR112018010639A2 (pt) | método de transfecção transitória para produção retroviral. | |
| BR112022016992A2 (pt) | Vacina com base em poxvírus recombinante contra ví-rus sars-cov-2 | |
| BR112016002614A8 (pt) | Imunocitoquina, ácido nucleico, vetor, célula hospedeira e composição farmacêutica | |
| BR112022024629A2 (pt) | Construtos anti-cd93 e seus usos | |
| BR112015002131A8 (pt) | Vírus vaccinia ankara modificado (mva) recombinante, composição farmacêutica e uso do referido mva recombinante | |
| MX2016008551A (es) | Moleculas artificiales de acido nucleico. | |
| BR112014018432A8 (pt) | Proteína, composição imunogênica, método para produzir proteína e para tratar ou prevenir doença, molécula de ácido nucleico, vetor, célula hospedeira, uso de uma proteína, e, uso de uma composição imunogênica | |
| BR112022026580A2 (pt) | Composições e métodos para induzir uma resposta imune contra coronavírus | |
| BR112022025733A2 (pt) | Vetores hvt recombinantes expressando hemaglutinina de influenza e composições imunogênicas, e produção e usos dos mesmos | |
| GEAP202516650A (en) | Stabilized pre-fusion hmpv fusion proteins | |
| BR112016011866A2 (pt) | vetores de composições e métodos para induzir uma resposta imune potencializada usando vetores de poxvírus | |
| CO2017011431A2 (es) | Proteínas de fusión de receptor de factor de crecimiento epidermal variante iii - mesotelina | |
| BR112023023558A2 (pt) | Anticorpos anti-tmprss6 e usos dos mesmos | |
| BR112023021654A2 (pt) | Vacina contra vírus | |
| BR112022011422A2 (pt) | Imunógenos para vírus da caxumba e do sarampo e seus usos | |
| BR112022010680A2 (pt) | Proteínas de ligação ao antígeno associado ao interferon e uso das mesmas | |
| BR112018072719A2 (pt) | molécula de ácido nucleico isolada, composição, e, métodos de indução de uma resposta imune contra o filovírus e o ebolavirus, de tratamento de um indivíduo que foi diagnosticado com ebolavirus e de prevenção da infecção por ebolavirus |